0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editor's Correspondence |

Cost-effectiveness of Chemoprophylaxis After Occupational Exposure to HIV

Steven David Pinkerton, PhD; David Robert Holtgrave, PhD; Heidi Jill Pinkerton, MD
Arch Intern Med. 1998;158(13):1469-1472. doi:.
Text Size: A A A
Published online

Extract

In reply

Frothingham raises an important point regarding the potential impact of serious treatment complications on the cost-effectiveness of therapeutic interventions. In our analysis of the cost-effectiveness of the use of postexposure prophylaxis (PEP) for health care workers who have been exposed through their occupations to the human immunodeficiency virus (HIV), we considered 2 cost components: the cost of counseling health care workers exposed to HIV on the use of PEP, and the cost of drugs for those who elect to use PEP.1 Diagnostic and treatment costs associated with adverse effects of the recommended antiretroviral treatment (a 4-week course of zidovudine, lamivudine, and indinavir) were not included in this base case analysis. Most documented complications of the recommended antiretroviral therapy (such as gastrointestinal problems, headaches, nausea, and fatigue) are relatively minor and typically resolve on cessation of therapy, although more serious adverse effects, including hyperbilirubinemia and kidney stones, have also been reported in association with the use of these drugs by patients with HIV. However, the toxic effects of short-course therapies used for persons who do not have HIV have not been well documented. As we noted in our article, the results of our analysis are sensitive to the costs associated with the administration of PEP, including monitoring and treating complications of antiretroviral therapy. If these costs are substantial, then PEP may not be cost-effective.1

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
/>
First page PDF preview

Figures

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Topics
PubMed Articles
Jobs
JAMAevidence.com
brightcove.createExperiences();